skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index
Show only
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
Material Type:
Article 		Add to My Research

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Cell, 2021-01, Vol.184 (1), p.169-183.e17 [Peer Reviewed Journal]

2020 Elsevier Inc. ;Copyright © 2020 Elsevier Inc. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020 Elsevier Inc. 2020 Elsevier Inc. ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2020.11.029 ;PMID: 33296701

Digital Resources/Online E-Resources

Citations Cited by
2
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Material Type:
Article 		Add to My Research

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

The Journal of infectious diseases, 2021-02, Vol.223 (2), p.197-205 [Peer Reviewed Journal]

The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. 2020 ;The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. ;ISSN: 0022-1899 ;EISSN: 1537-6613 ;DOI: 10.1093/infdis/jiaa618 ;PMID: 33535236

Full text available

Citations Cited by
3
Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice
Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice
Material Type:
Article 		Add to My Research

Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice

npj vaccines, 2022-05, Vol.7 (1), p.55-55, Article 55 [Peer Reviewed Journal]

2022. The Author(s). ;The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2022 ;ISSN: 2059-0105 ;EISSN: 2059-0105 ;DOI: 10.1038/s41541-022-00472-2 ;PMID: 35606518

Full text available

Citations Cited by
4
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
Material Type:
Article 		Add to My Research

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2

Cell, 2020-11, Vol.183 (5), p.1367-1382.e17 [Peer Reviewed Journal]

2020 The Authors ;Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved. ;2020. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.elsevier.com/legal/elsevier-website-terms-and-conditions ;2020 The Authors 2020 ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2020.10.043 ;PMID: 33160446

Digital Resources/Online E-Resources

Citations Cited by
5
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
Material Type:
Article 		Add to My Research

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

Cell, 2021-10, Vol.184 (21), p.5432-5447.e16 [Peer Reviewed Journal]

2021 Elsevier Inc. ;Copyright © 2021 Elsevier Inc. All rights reserved. ;2021 Elsevier Inc. 2021 Elsevier Inc. ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2021.09.015 ;PMID: 34619077

Full text available

Citations Cited by
6
F‐domain valency determines outcome of signaling through the angiopoietin pathway
F‐domain valency determines outcome of signaling through the angiopoietin pathway
Material Type:
Article 		Add to My Research

F‐domain valency determines outcome of signaling through the angiopoietin pathway

EMBO reports, 2021-12, Vol.22 (12), p.e53471-n/a [Peer Reviewed Journal]

2021 The Authors ;2021 The Authors. ;2021 EMBO ;ISSN: 1469-221X ;EISSN: 1469-3178 ;DOI: 10.15252/embr.202153471 ;PMID: 34698433

Full text available

Citations Cited by
7
Functional SARS-CoV-2-specific immune memory persists after mild COVID-19
Functional SARS-CoV-2-specific immune memory persists after mild COVID-19
Material Type:
Article 		Add to My Research

Functional SARS-CoV-2-specific immune memory persists after mild COVID-19

The Journal of immunology (1950), 2021-05, Vol.206 (1_Supplement), p.62-62.06 [Peer Reviewed Journal]

ISSN: 0022-1767 ;EISSN: 1550-6606 ;DOI: 10.4049/jimmunol.206.Supp.62.06

Full text available

Citations Cited by
8
Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses
Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses
Material Type:
Article 		Add to My Research

Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses

Immunity (Cambridge, Mass.), 2023-10, Vol.56 (10), p.2425 [Peer Reviewed Journal]

ISSN: 1097-4180 ;EISSN: 1097-4180 ;DOI: 10.1016/j.immuni.2023.08.011

Digital Resources/Online E-Resources

Citations Cited by
9
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
Material Type:
Article 		Add to My Research

Adjuvanting a subunit COVID-19 vaccine to induce protective immunity

Nature (London), 2021-06, Vol.594 (7862), p.253-258 [Peer Reviewed Journal]

COPYRIGHT 2021 Nature Publishing Group ;Copyright Nature Publishing Group Jun 10, 2021 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-021-03530-2 ;PMID: 33873199

Full text available

Citations Cited by
10
Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens
Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens
Material Type:
Article 		Add to My Research

Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens

Cell reports. Medicine, 2022-10, Vol.3 (10), p.100780, Article 100780 [Peer Reviewed Journal]

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. ;2022 The Author(s) 2022 ;ISSN: 2666-3791 ;EISSN: 2666-3791 ;DOI: 10.1016/j.xcrm.2022.100780 ;PMID: 36206752

Full text available

Citations Cited by
11
Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection
Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection
Material Type:
Article 		Add to My Research

Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection

The Journal of infectious diseases, 2020-09 [Peer Reviewed Journal]

The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. ;EISSN: 1537-6613 ;PMID: 33000143

Full text available

Citations Cited by
12
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
Material Type:
Article 		Add to My Research

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

bioRxiv, 2021-03

2021. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;DOI: 10.1101/2021.03.15.435528

Digital Resources/Online E-Resources

Citations Cited by
13
Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates
Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates
Material Type:
Article 		Add to My Research

Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates

bioRxiv, 2021-02

2021. Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the associated terms available at https://www.biorxiv.org/content/10.1101/2021.02.10.430696v1 ;DOI: 10.1101/2021.02.10.430696

Digital Resources/Online E-Resources

Citations Cited by
14
PREPARATION OF AMINO-ACETAL
PREPARATION OF AMINO-ACETAL
Material Type:
Article 		Add to My Research

PREPARATION OF AMINO-ACETAL

Journal of the American Chemical Society, 1929-12, Vol.51 (12), p.3612-3613 [Peer Reviewed Journal]

ISSN: 0002-7863 ;EISSN: 1520-5126 ;DOI: 10.1021/ja01387a016

Full text available

Citations Cited by
15
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2
Material Type:
Article 		Add to My Research

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2

bioRxiv, 2020-08

2020. This article is published under http://creativecommons.org/licenses/by-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;DOI: 10.1101/2020.08.11.247395

Digital Resources/Online E-Resources

Citations Cited by
16
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples
Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples
Material Type:
Article 		Add to My Research

Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples

bioRxiv, 2021-07

2021. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;DOI: 10.1101/2021.07.02.450915

Digital Resources/Online E-Resources

Citations Cited by
17
VENEER-BOX-SHAPING MACHINE
VENEER-BOX-SHAPING MACHINE
Material Type:
Patent 		Add to My Research

VENEER-BOX-SHAPING MACHINE

Digital Resources/Online E-Resources

Citations Cited by

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Show only

  1. Peer-reviewed Journals (12)

Refine My Results

Creation Date 

From To
Refine
  1. Before 1910  (1)
  2. 1910 To 1929  (1)
  3. 1930 To 2019  (1)
  4. 2020 To 2021  (12)
  5. After 2021  (3)
  6. More options open sub menu

Resource Type 

  1. Articles  (16)
  2. Patents  (1)
  3. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait